All In Biotech

Drug Trial Radar · NCT06346197

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Dec 8, 2025

Primary completion

May 15, 2028

Study completion May 15, 2028

Sponsor

Lead sponsor
Centre Leon BerardAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Agenus Inc.
First posted
Apr 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CIME is a multicenter, randomised, comparative, open-label phase III study aiming to compare the survival of patients suffering from MSI-H/dMMR locally advanced or metastatic oeasogastric adenocarcinoma treated by a bi-immunotherapy (experimental arm) versus standard current treatment (FOLFOX/XELOX + nivolumab : standard arm).

Conditions

  • Gastric Cancer
  • MSI-H
  • Metastatic Cancer
  • Advanced Cancer

Interventions

  • BalstilimabDrug

    Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.

  • BotensilimabDrug

    Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.

  • Folfox ProtocolDrug

    oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

  • XELOXDrug

    Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

  • NivolumabDrug

    240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival of patientsTime frame: at least 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • CHU de Brest

    Brest, France · Recruiting

  • CHU de Clermont-Ferrand

    Clermont-Ferrand, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Hôpital Privé Jean Mermoz

    Lyon, France · Recruiting

  • Institut Paoli Calmettes

    Marseille, France · Recruiting

  • Institut Mutualiste Montsouris

    Paris, France · Recruiting

  • CHU de Poitiers

    Poitiers, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.